A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis

Cancer Research

Volumn 69, Issue 3, 2009, Pages 810-818

  Hu, Miaofen G ^a,f   Deshpande, Amit ^c   Enos, Miriam ^a   Mao, Daqin ^a   Hinds, Elisabeth A ^a   Hu, Guo Fu ^b   Chang, Rui ^a   Guo, Zhuyan ^a,d   Dose, Marei ^a,e   Mao, Changchuin ^a   Tsichlis, Philip N ^a   Gounari, Fotini ^a,e   Hinds, Philip W ^a,f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 6; NOTCH RECEPTOR; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL COUNT; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; THYMOCYTE; THYMUS ATROPHY; THYMUS LYMPHOMA;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE 6; FEMALE; LYMPHOMA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; ONCOGENE PROTEIN V-AKT; RECEPTORS, NOTCH; T-LYMPHOCYTES; THYMUS GLAND; THYMUS NEOPLASMS;

EID: 59149089409     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2473     Document Type: Article

References (38)

1. Wilson A, MacDonald HR, Radtke F. Notch 1-deficient common lymphoid precursors adopt a B cell fate in the thymus. J Exp Med 2001;194:1003-12.
2. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284:770-6.
3. Radtke F, Wilson A, Stark G, et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 1999;10:547-58.
4. Schmitt TM, Zuniga-Pflucker JC. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity 2002;17:749-56.
5. Aster JC, Pear WS, Blacklow SC. Notch signaling in leukemia. Annu Rev Pathol 2008;3:587-613.
6. Ciofani M, Zuniga-Pflucker JC. Notch promotes survival of pre-T cells at the β-selection checkpoint by regulating cellular metabolism. Nat Immunol 2005;6:881-8.
7. 1-phase progression. Genes Dev 1999;13:1501-12.
8. Grossel MJ, Hinds PW. From cell cycle to differentiation: an expanding role for cdk6. Cell Cycle 2006;5:266-70.
9. Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 1999;287:821-8.
10. Sicinska E, Aifantis I, Le Cam L, et al. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 2003;4:451-61.
11. Rane SG, Dubus P, Mettus RV, et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia. Nat Genet 1999;22:44-52.
12. Martin A, Odajima J, Hunt SL, et al. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 2005;7:591-8.
13. Malumbres M, Sotillo R, Santamaria D, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004;118:493-504.
14. 1-phase cell cycle genes during hematopoietic lineage. Biochem Biophys Res Commun 1997;231:73-6.
15. Chilosi M, Doglioni C, Yan Z, et al. Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia. Am J Pathol 1998;152:209-17.
16. Lien HC, Lin CW, Huang PH, Chang ML, Hsu SM. Expression of cyclin-dependent kinase 6 (cdk6) and frequent loss of CD44 in nasal-nasopharyngeal NK/T-cell lymphomas: comparison with CD56-negative peripheral T-cell lymphomas. Lab Invest 2000;80:893-900.
17. Nagel S, Leich E, Quentmeier H, et al. Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma. Leukemia 2008;22:387-92.
18. Schwartz R, Engel I, Fallahi-Sichani M, Petrie HT, Murre C. Gene expression patterns define novel roles for E47 in cell cycle progression, cytokine-mediated signaling, and T lineage development. Proc Natl Acad Sci U S A 2006;103:9976-81.
19. Hu MG, Hu GF, Kim Y, et al. Role of p12(CDK2-AP1) in transforming growth factor-β1-mediated growth suppression. Cancer Res 2004;64:490-9.
20. Gounari F, Chang R, Cowan J, et al. Loss of adenomatous polyposis coli gene function disrupts thymic development. Nat Immunol 2005;6:800-9.
21. Gounari F, Aifantis I, Martin C, et al. Tracing lymphopoiesis with the aid of a pTα-controlled reporter gene. Nat Immunol 2002;3:489-96.
22. Veiga-Fernandes H, Rocha B. High expression of active CDK6 in the cytoplasm of CD8 memory cells favors rapid division. Nat Immunol 2004;5:31-7.
23. Tsutsui T, Hesabi B, Moons DS, et al. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol 1999;19:7011-9.
24. Godfrey DI, Zlotnik A. Control points in early T-cell development. Immunol Today 1993;14:547-53.
25. Schwarz BA, Bhandoola A. Circulating hematopoietic progenitors with T lineage potential. Nat Immunol 2004;5:953-60.
26. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-511.
27. Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 1998;273:29864-72.
28. Malstrom S, Tili E, Kappes D, Ceci JD, Tsichlis PN. Tumor induction by an Lck-MyrAkt transgene is delayed by mechanisms controlling the size of the thymus. Proc Natl Acad Sci U S A 2001;98:14967-72.
29. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-95.
30. Zweidler-McKay PA, Pear WS. Notch and T cell malignancy. Semin Cancer Biol 2004;14:329-40.
31. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996;15:6541-51.
32. Mao C, Tili EG, Dose M, et al. Unequal contribution of Akt isoforms in the double-negative to double-positive thymocyte transition. J Immunol 2007;178:5443-53.
33. Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001;114:2903-10.
34. Nie L, Xu M, Vladimirova A, Sun XH. Notch-induced E2A ubiquitination and degradation are controlled by MAP kinase activities. EMBO J 2003;22:5780-92.
35. Talora C, Campese AF, Bellavia D, et al. Pre-TCR-triggered ERK signalling-dependent downregulation of E2A activity in Notch3-induced T-cell lymphoma. EMBO Rep 2003;4:1067-72.
36. Engel I, Murre C. Disruption of pre-TCR expression accelerates lymphomagenesis in E2A-deficient mice. Proc Natl Acad Sci U S A 2002;99:11322-7.
37. Reizis B, Leder P. Direct induction of T lymphocyte-specific gene expression by the mammalian Notch signaling pathway. Genes Dev 2002;16:295-300.
38. Boyer LA, Lee TI, Cole MF, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005;122:947-56.